Trials / Terminated
TerminatedNCT02029586
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Yungjin Pharm. Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MB12066 200mg | oral administration, 100mg bid |
| DRUG | Placebo | oral administration, 100mg bid |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2014-01-08
- Last updated
- 2017-12-21
Locations
10 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02029586. Inclusion in this directory is not an endorsement.